Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios
- PMID: 15304429
- DOI: 10.1124/dmd.104.000794
Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios
Abstract
Glucuronidation is a listed clearance mechanism for 1 in 10 of the top 200 prescribed drugs. The objective of this article is to encourage those studying ligand interactions with UDP-glucuronosyltransferases (UGTs) to adequately consider the potential consequences of in vitro UGT inhibition in humans. Spurred on by interest in developing potent and selective inhibitors for improved confidence around UGT reaction phenotyping, and the increased availability of recombinant forms of human UGTs, several recent studies have reported in vitro inhibition of UGT enzymes. In some cases, the observed potency of UGT inhibitors in vitro has been interpreted as having potential relevance in humans via pharmacokinetic drug-drug interactions. Although there are reported examples of clinically relevant drug-drug interactions for UGT substrates, exposure increases of the aglycone are rarely greater than 100% in the presence of an inhibitor relative to its absence (i.e., AUCi/AUC < or = 2). This small magnitude in change is in contrast to drugs primarily cleared by cytochrome P450 enzymes, where exposures have been reported to increase as much as 35-fold on coadministration with an inhibitor (e.g., ketoconazole inhibition of CYP3A4-catalyzed terfenadine metabolism). In this article the evidence for purported clinical relevance of potent in vitro inhibition of UGT enzymes will be assessed, taking the following into account: in vitro data on the enzymology of glucuronide formation from aglycone, pharmacokinetic principles based on empirical data for inhibition of metabolism, and clinical data on the pharmacokinetic drug-drug interactions of drugs primarily cleared by glucuronidation.
Copyright 2004 The American Society for Pharmacology and Experimental Therapeutics
Similar articles
-
In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans.J Pharmacol Exp Ther. 2010 Aug;334(2):609-18. doi: 10.1124/jpet.110.167916. Epub 2010 May 18. J Pharmacol Exp Ther. 2010. PMID: 20484152
-
The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.Drug Metab Rev. 2010 Feb;42(1):196-208. doi: 10.3109/03602530903210716. Drug Metab Rev. 2010. PMID: 19795925
-
Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.Drug Metab Dispos. 2008 Feb;36(2):361-7. doi: 10.1124/dmd.107.018705. Epub 2007 Nov 12. Drug Metab Dispos. 2008. PMID: 17998297
-
In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.Biochem Pharmacol. 2006 May 28;71(11):1531-9. doi: 10.1016/j.bcp.2005.12.019. Epub 2006 Feb 7. Biochem Pharmacol. 2006. PMID: 16455060 Review.
-
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacol Ther. 2005 Apr;106(1):97-132. doi: 10.1016/j.pharmthera.2004.10.013. Epub 2005 Jan 12. Pharmacol Ther. 2005. PMID: 15781124 Review.
Cited by
-
Cannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug-Drug Interactions.Pharmaceutics. 2024 Mar 18;16(3):418. doi: 10.3390/pharmaceutics16030418. Pharmaceutics. 2024. PMID: 38543313 Free PMC article.
-
Graphene quantum dots blocking the channel egresses of cytochrome P450 enzyme (CYP3A4) reveals potential toxicity.Sci Rep. 2023 Nov 30;13(1):21091. doi: 10.1038/s41598-023-48618-z. Sci Rep. 2023. PMID: 38036640 Free PMC article.
-
Establishment of UGT1A1-knockout human iPS-derived hepatic organoids for UGT1A1-specific kinetics and toxicity evaluation.Mol Ther Methods Clin Dev. 2023 Aug 11;30:429-442. doi: 10.1016/j.omtm.2023.08.003. eCollection 2023 Sep 14. Mol Ther Methods Clin Dev. 2023. PMID: 37663646 Free PMC article.
-
Induced Fit Describes Ligand Binding to Membrane-Associated Cytochrome P450 3A4.Mol Pharmacol. 2023 Oct;104(4):154-163. doi: 10.1124/molpharm.123.000698. Epub 2023 Aug 3. Mol Pharmacol. 2023. PMID: 37536953
-
Dissecting the human gut microbiome to better decipher drug liability: A once-forgotten organ takes center stage.J Adv Res. 2023 Oct;52:171-201. doi: 10.1016/j.jare.2023.07.002. Epub 2023 Jul 5. J Adv Res. 2023. PMID: 37419381 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical